Is Coronary Brachytherapy Staging a Comeback for the Treatment of In-Stent Restenosis?
Htoo KyawGurpreet JohalMaheedhar GedelaNitin BarmanAnnapoorna KiniSamin K SharmaPublished in: Current cardiology reports (2021)
Drug-eluting stents have an inherent limitation as they leave a permanent metal layer inside an artery when deployed. Recently, drug-coated balloon technology has emerged to treat coronary artery disease as a combination of balloon angioplasty and local drug delivery without leaving a metal layer behind. Recent European guidelines recommended using drug-coated balloons when treating in-stent restenosis treatment, while the US guidelines have not yet addressed the use of drug-coated balloons in such cases. Coronary brachytherapy is a valuable addition to treat these challenging diseases despite several logistic issues. If there are newer technologies with easier setup, such as drug-coated balloons, coronary brachytherapy resurgence is improbable in the contemporary era, although it may not become obsolete.
Keyphrases
- coronary artery disease
- high dose
- coronary artery
- drug delivery
- radiation therapy
- adverse drug
- locally advanced
- percutaneous coronary intervention
- squamous cell carcinoma
- clinical practice
- cardiovascular events
- heart failure
- coronary artery bypass grafting
- low dose
- cardiovascular disease
- combination therapy
- left ventricular
- smoking cessation